Africa institutional business volatility
Africa institutional (anti-malarial) sales declined 16% YoY due to unpredictable procurement agency funding.
AJANTPHARM / Q1-FY24 / risks
Keep the risk register visible.
Ajanta Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Chantix launch uncertainty
Chantix launch depends on FDA approval; management could not provide a firm timeline, citing regulatory dependence.
Price erosion in US generics
While price erosion has moderated to high single digits, further acceleration remains a risk given market dynamics.